01—Abstract
Summary
Summary of the 10-Q filed May 9, 2023. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported first-quarter 2023 net product revenues of $363.4 milliona, up from $310.3 million a year earlier, and total revenues of $408.8 million versus $356.0 million.
CABOMETYX net product revenues were $361.8 millionb, and the filing attributes the increase primarily to a 10% rise in CABOMETYX units sold, related to the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC, plus an 8% increase in average net selling price. Net income was $40.0 million, or $0.12 per diluted share, compared with $68.6 million, or $0.21 per share, in the prior-year quarter. Research and development expenses rose to $234.2 million from $156.7 million, driven mainly by a $35.0 million development milestone paid to Sairopa B.V. upon the effective date of the initial new drug application for ADU-1805, along with higher personnel and other development costs.
The balance sheet remained strong, with $2.1 billionc in cash, cash equivalents, restricted cash equivalents and investments as of March 31, 2023. The company stated that its current cash, short-term investments, net product revenues and collaboration revenues should fund operations for at least 12 months and thereafter for the foreseeable future. In March 2023, the Board authorized a share repurchase program of up to $550 million of common stock before the end of 2023, though no shares were repurchased during the quarter.
The filing highlights ongoing legal and competitive risk to CABOMETYX. Generic ANDA filers MSN, Teva and Cipla have challenged its patents. The Delaware District Court ruled in January 2023 against MSN's invalidity challenge in MSN I, with judgment that generic approval cannot take effect before August 14, 2026.
The MSN II bench trial is scheduled for October 2023, and the Cipla case has been administratively stayed. The company stated it cannot determine the likelihood or amount of loss from an unfavorable outcome.
02—Key points
Key Highlights
- Total revenues rose to $408.8 million from $356.0 million, with net product revenues of $363.4 million, of which CABOMETYX accounted for $361.8 million.
- Research and development expenses increased to $234.2 million from $156.7 million, including a $35.0 million milestone paid to Sairopa B.V. for ADU-1805.
- Net income was $40.0 million, or $0.12 per diluted share, versus $68.6 million, or $0.21 per diluted share, in the prior-year quarter.
- Cash, cash equivalents, restricted cash equivalents and investments totaled $2.1 billion at March 31, 2023.
- The Board authorized a share repurchase program of up to $550 million before the end of 2023; no shares were repurchased in the quarter.
- Delaware District Court ruled in January 2023 that MSN's ANDA product does not infringe U.S. Patent No. 8,877,776, and set the earliest generic approval date at August 14, 2026, in the MSN I litigation.
- Multiple generic ANDA filers (MSN, Teva and Cipla) continue to challenge CABOMETYX patents, and the filing says generic approval could significantly reduce U.S. CABOMETYX revenue.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2024, Exelixis kept $0.10.
- Revenue$408.8M100.0%
- Cost of revenue−$14.3M3.5%
- Gross profit$394.5M96.5%
- Operating costs−$365.6M89.4%
- Operating income$28.8M7.1%
- Interest, other & tax$11.2M2.7%
- Net income$40.0M9.8%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2024filed May 9, 2023Financial Statements
Q1 FY2024 against Q1 FY2023
| Line item | Q1 FY2024Q1 FY2023 | Change |
|---|---|---|
| Revenue | $408.79M$355.98M | +14.8% |
| Cost of Revenue | $14.31M$13.20M | +8.4% |
| Gross Profit | $394.47M$342.78M | +15.1% |
| R&D Expenses | $234.25M$156.67M | +49.5% |
| SG&A Expenses | $131.40M$102.86M | +27.7% |
| Operating Expenses | $379.96M$272.74M | +39.3% |
| Operating Income | $28.83M$83.24M | −65.4% |
| Net Income | $40.03M$68.57M | −41.6% |
| EPS (Basic) | $0.12$0.21 | −42.9% |
| EPS (Diluted) | $0.12$0.21 | −42.9% |
| Shares Outstanding (Basic) | 324.42M319.58M | +1.5% |
| Shares Outstanding (Diluted) | 326.28M323.29M | +0.9% |
05—Questions
Frequently Asked Questions
What drove the increase in net product revenues this quarter?
The filing attributes the increase primarily to a 10% rise in the number of CABOMETYX units sold, linked to the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment for advanced RCC, and to a lesser extent an 8% increase in the average net selling price of CABOMETYX.
Why did research and development expenses increase so much?
The filing cites higher license and other collaboration costs, including a $35.0 million development milestone paid to Sairopa B.V. upon the effective date of the IND for ADU-1805, as well as higher personnel expenses, other development costs such as manufacturing, and other research and development expenses, partially offset by lower stock-based compensation.
Is the company able to fund its operations?
Yes. The company states that its current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable it to maintain operations for at least 12 months and thereafter for the foreseeable future. It reported $2.1 billion in cash, cash equivalents, restricted cash equivalents and investments.
What is the main legal risk to CABOMETYX revenue?
Several generic manufacturers have filed ANDAs seeking approval to sell generic CABOMETYX before its patents expire. The filing says the approval and launch of any generic version could significantly decrease U.S. CABOMETYX revenue. The company says it cannot determine the likelihood or estimate the amount of loss from an unfavorable outcome.
What capital return actions were announced?
In March 2023, the Board authorized a share repurchase program of up to $550 million of common stock before the end of 2023. The company did not repurchase any shares during the three months ended March 31, 2023, and the program may be modified, suspended or discontinued at any time.
06—Continue